Delcath stock yahoo

DCTH Stock Message Board for Investors. Delcath Systems Inc. Stock Price, News and Company Updates. Message Board Total Posts: 331 Investors Catching Stocks Delcath Systems, Inc. (DCTH)

DCTH interactive stock chart | Delcath Systems, Inc. stock ... At Yahoo Finance, you get free stock quotes, the latest news, portfolio management resources, international market data, social interaction and mortgage rates to help you manage your financial life. Back. Delcath Systems, Inc. (DCTH) Add to watchlist. Other OTC - Other OTC Delayed price. Currency in USD. 8.35 0.00 (0.00%) Delcath Systems (DCTH) Stock Quotes | Nasdaq Delcath Systems (DCTH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Delcath Systems, Inc. News - Investing, Stock Quotes and ...

Apr 09, 2013 · Delcath shares fall further on job cuts. SHARE ACTION: Delcath stock sank 16 cents, or 9.7 percent, to $1.49 in afternoon trading. The shares fell 12 cents, or 6.8 percent, to $1.65 on Monday Delcath Systems (DCTH) Stock Price History | wallmine AU Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers.The company's investigational products include melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system … Delcath Systems, Inc. | Stock Discussion Forums

Delcath slips on change to Chemosat FDA filing - Yahoo

Prev Close 12.19, 52 Wk Low 5.15. Open 0.00, 52 Wk High 160.30. Day Low 0.00, Volume 0.00. Day High 0.00, Avg 10D Vol 0.00  24 Dec 2019 A reverse stock split went into effect today for Delcath Systems (OTC:DCTH) — developer of the Chemostat hepatic delivery system for treating 

Find out all the key statistics for Delcath Systems, Inc. (DCTH), including valuation measures, fiscal year financial statistics, trading record, share statistics and 

Delcath are investigating the potential for our therapy in two key areas: 1. FOCUS 301A Registration study—for patients with ocular melanoma metastatic to the liver. 2. ALIGN Phase 3 study to investigate Melphalan/Hepatic Delivery System vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma. Delcath Systems, Inc. (DCTH) stock price, quote, history ... Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that the Company’s Board of Directors has authorized a 1-for-700 reverse stock split of the Company’s common stock. Delcath Systems, Inc. (DCTH) Stock Analysis & News ... Get breaking news and analysis on Delcath Systems, Inc. (DCTH) stock, price quote and chart, trading and investing tools.

Apr 09, 2013 · He kept an "Outperform" rating on Delcath shares with a price target of $5. SHARE ACTION: Delcath stock sank 16 cents, or 9.7 percent, to $1.49 in afternoon trading. The shares fell 12 cents, or 6.8 percent, to $1.65 on Monday. Delcath shares have ranged between $1.01 and $3.22 in the last year.

Delcath Systems, Inc. (DCTH) Stock Price, Quote ... - Yahoo

Find the latest Delcath Systems, Inc. (DCTH) stock discussions in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.